Evaluation of RAW 264.7 macrophages treated with epigallocatechin-3-gallate and thymoquinone

Biomedical Sciences Instrumentation

Volumn 45, Issue , 2009, Pages 346-351

  Wilkins, Reneé ^a   Tucci, Michelle ^a   Benghuzzi, Ham ^a  

^a UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

Author keywords

Antioxidants; Glutathione; IL 1; RAW 264.7

Indexed keywords

ANTIOXIDANTS; CELL NUMBER; CELL VIABILITY; CELLULAR FUNCTION; CELLULAR MORPHOLOGY; CELLULAR PROCESS; CELLULAR VIABILITY; CONTROL VALUES; EFFECTIVE CONCENTRATION; EPIGALLOCATECHIN-3-GALLATE; GLUTATHIONE; HIGH DOSE; HIGH-DOSE TREATMENT; IL-1; IMMUNE CELLS; IMMUNE SYSTEMS; IN-CELL; INFLAMMATORY PROCESS; INTRACELLULAR GLUTATHIONE LEVELS; RAW 264.7; REACTIVE OXYGEN SPECIES; SHORT PERIODS; THYMOQUINONE; TREATMENT GROUP; WATERSOLUBLE;

ANTIGEN-ANTIBODY REACTIONS; MACROPHAGES; MORPHOLOGY; OXYGEN; PATHOLOGY;

CONCENTRATION (PROCESS);

ANTIOXIDANT; CYTOKINE; EPIGALLOCATECHIN GALLATE; GLUTATHIONE; INTERLEUKIN 1BETA; THYMOQUINONE;

ANIMAL CELL; ANTIOXIDANT ACTIVITY; CELL COUNT; CELL FUNCTION; CELL LEVEL; CELL STRUCTURE; CELL VIABILITY; CONCENTRATION RESPONSE; CONFERENCE PAPER; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG MECHANISM; LIPOPHILICITY; MACROPHAGE; MOUSE; NONHUMAN;

EID: 65749089805     PISSN: 00678856     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (19)

1. I. Riott, J. Brostoff, and D. Male, Immunology (6th Ed.), London: Harcourt Publishers Limited.
2. L. Bosca, M. Zeini, P. G. Traves, and S. Hortelano, "Nitric oxide and cell viability in inflammatory cells: A role for NO in macrophage function and fate," Toxicology, vol. 208, pp. 249-58, 2005.
3. A. Barzilai and K. Yamamoto, "DNA damage responses to oxidative stress," DNA Repair, vol. 3, pp. 1109-14, 2004.
4. I. A. Cotgreave and R. G. Gerdes, "Recent trends in glutathione biochemistry - glutathione-protein interactions: A molecular link between oxidative stress and cell proliferation?," Biochemical and Biophysical Research Communications, vol. 242, pp. 1-9, 1998.
5. L. B. Maçao, D. Wilhelm Filho, R. C. Pedrosa, A. Pereira, P. Backes, M. A. Torres, T. S. Fröde, "Antioxidant therapy attenuates oxidative stress in chronic cardiopathy associated with Chagas' disease," International Journal of Cardiology, vol. 123, pp. 43-9, 2007.
6. H. Osiecki, "The role of chronic inflammation in cardiovascular disease and its regulation by nutrients," Alternative Medicine Review: A Journal of Clinical Therapeutic, vol. 9, pp. 32-53, 2004.
7. I. Rahman and I. Kilty, "Antioxidant therapeutic targets in COPD," Current Drug Targets, vol. 7, pp. 707-20, 2006.
8. H. S. El-Abhar, D. M. Abdallah, and S. Saleh, "Gastroprotective activity of Nigella sativa oil and its constituent, thymoquinone, against gastric mucosal injury induced by ischaemia/reperfusion in rats," Journal of Ethnopharmacology, vol. 84, pp. 251-8, 2003.
9. M. A. Baker, G. J. Cerniglia, A. Zaman, "Microtiter plate assay for the measurement of glutathione and glutathione disulfide in large numbers of biological samples," Analytical Biochemistry, vol. 190, pp. 360-65, 1990.
10. R. N. Fiorini, J. L. Donovan, D. Rodwell, Z. Evans, G. Cheng, H. D. May, et al, "Short-term administration of (-)-epigallocatechin gallate reduces hepatic steatosis and protects against warm hepatic ischemia/ reperfusion injury in steatotic mice," Liver Transplantation, vol. 11, pp. 298-308, 2005.
11. J. M. Jimenez-Lopez and A. I. Cederbaum, "Green tea polyphenol epigallocatechin-3-gallate protects HepG2 cells against CYP2E1-dependent toxicity," Free Radical Biology & Medicine, vol. 36, pp. 359-70, 2004.
12. N. Kuzu, I. H. Bahcecioglu, A. F. Dagli, I. H. Ozercan, B. Ustündag, and K. Sahin, "Epigallocatechin gallate attenuates experimental non-alcoholic steatohepatitis induced by high fat diet," Journal of Gastroenterology and Hepatology, vol. 23, pp. 465-70, 2007.
13. S. I. Rizvi, M. A. Zaid, R. Anis, and N. Mishra, "Protective role of tea catechins against oxidation-induced damage of type 2 diabetic erythrocytes," Clinical and Experimental Pharmacology & Physiology vol. 32, pp. 70-5, 2005.
14. C. H. Ko, K. Li, P. C, Ng, K. Fung, C. L. Li, R. P. Wong, et al, "Pro-oxidative effects of tea and polyphenols, epigallocatechin-3-gallate and epigallocatechin, on G6PD-deficient erythrocytes in vitro," International Journal of Molecular Medicine vol. 18, pp. 987-94, 2006.
15. M. Kanter, H. Demir, C. Karakaya, and H. Ozbek, "Gastroprotective activity of Nigella sativa L oil and its constituent, thymoquinone against acute alcohol-induced gastric mucosal injury in rats," World Journal of Gastroenterology, vol. 11, pp. 6662-6, 2005.
16. A. A. Al-Majed, F. A. Al-Omar, and M. N. Nagi, "Neuroprotective effects of thymoquinone against transient forebrain ischemia in the rat hippocampus," European Journal of Pharmacology, vol. 543, pp. 40-7, 2006.
17. M. M. Khattab and M. N. Nagi, "Thymoquinone supplementation attenuates hypertension and renal damage in nitric oxide deficient hypertensive rats," Phytotherapy Research, vol. 21, pp. 410-4, 2007.
18. A. Mohamed, D. Afridi, O. Garani, and M. Tucci, "Thymoquinone inhibits the activation of NF-kappaB in the brain and spinal cord of experimental autoimmune encephalomyelitis," Biomedical Sciences Instrumentation vol. 41, pp. 388-93, 2005.
19. A. Mohamed, A. Shoker, F. Bendjelloul, A. Mare, M. Alzrigh, H. Benghuzzi, et al, "Improvement of experimental allergic encephalomyelitis (EAE) by thymoquinone; an oxidative stress inhibitor," Biomedical Sciences Instrumentation, vol. 39, pp. 440-5, 2003.